NZ732628A - Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof - Google Patents

Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof

Info

Publication number
NZ732628A
NZ732628A NZ732628A NZ73262815A NZ732628A NZ 732628 A NZ732628 A NZ 732628A NZ 732628 A NZ732628 A NZ 732628A NZ 73262815 A NZ73262815 A NZ 73262815A NZ 732628 A NZ732628 A NZ 732628A
Authority
NZ
New Zealand
Prior art keywords
binding specificity
making
methods
bispecific tetravalent
family members
Prior art date
Application number
NZ732628A
Inventor
Zeren Gao
phil Tan
Brian Kovacevich
Blair Renshaw
Jeffrey Adamo
Nga Sze Amanda Mak
Shi Zhuo
Lan Chen
Zhu Yi
Original Assignee
Systimmune Inc
Sichuan Baili Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systimmune Inc, Sichuan Baili Pharmaceutical Co Ltd filed Critical Systimmune Inc
Publication of NZ732628A publication Critical patent/NZ732628A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

A bispecific tetravalent antibody comprising an IgG having a pair of heavy chains and a pair of light chains, and two scFv components being connected to either C or N terminals of the heavy or light chains. The bispecific tetravalent antibody may have a binding specificity for two different members of EGFR family. In an embodiment, each scFv domain is connected to the C-terminus of either of the IgG1 heavy chains. In a further embodiment, the tetravalent antibodies described herein have a binding specificity for EGFR and HER3.
NZ732628A 2014-12-22 2015-12-19 Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof NZ732628A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462095348P 2014-12-22 2014-12-22
PCT/US2015/066951 WO2016106157A1 (en) 2014-12-22 2015-12-19 Bispecific tetravalent antibodies and methods of makiing and using thereof

Publications (1)

Publication Number Publication Date
NZ732628A true NZ732628A (en) 2019-01-25

Family

ID=56151464

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ732628A NZ732628A (en) 2014-12-22 2015-12-19 Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof

Country Status (12)

Country Link
US (2) US10717783B2 (en)
EP (2) EP3237006B1 (en)
JP (2) JP6947639B2 (en)
KR (3) KR102590385B1 (en)
CN (11) CN113150165A (en)
AU (1) AU2015369831B2 (en)
CA (2) CA3138083A1 (en)
ES (1) ES2962675T3 (en)
IL (3) IL286835B2 (en)
NZ (1) NZ732628A (en)
SG (1) SG11201704741PA (en)
WO (2) WO2016106158A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113150165A (en) * 2014-12-22 2021-07-23 西雅图免疫公司 Bispecific tetravalent antibodies and methods of making and using same
CN106632681B (en) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 Anti- EGFR and AntiCD3 McAb bispecific antibody and its application
CN108948195B (en) * 2017-05-23 2022-05-31 胡毅 anti-EGFR/PD-L1 double-targeting antibody, preparation method and application thereof
JP7323513B2 (en) * 2017-06-25 2023-08-08 システィミューン， インク． ANTI-4-1BB ANTIBODY AND METHOD OF PRODUCTION AND USAGE THEREOF
CA3069238A1 (en) * 2017-11-02 2019-05-09 Systimmune, Inc. Bispecific antibodies and methods of making and using thereof
US11708410B2 (en) 2018-01-15 2023-07-25 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against TIGIT
CN107974461A (en) * 2018-01-18 2018-05-01 东北农业大学 A kind of construction of eukaryotic expression vector method of high efficient expression anti-hEGFR genes
CN108220244A (en) * 2018-01-18 2018-06-29 东北农业大学 Chinese hamster ovary celI strain, screening technique and its production technology of a kind of antibody gene containing recombinant human epidermal growth factor acceptor
KR20200143436A (en) * 2018-04-13 2020-12-23 아피메트 게엠베하 NK cell binding antibody fusion construct
US20210115152A1 (en) * 2018-05-16 2021-04-22 Arbele Limited Composition of bispecific antibodies and method of use thereof
JP7193058B2 (en) 2018-08-08 2022-12-20 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） インコーポレイテッド Recombinant bifunctional protein targeting CD47 and HER2
CN110850068B (en) * 2018-08-21 2023-08-15 上海恒润达生生物科技股份有限公司 Chimeric antigen receptor affinity detection method
CA3115545A1 (en) * 2018-11-13 2020-05-22 Jn Biosciences Llc Bispecific antibodies for activation of immune cells
MX2022001682A (en) 2019-08-08 2022-05-13 Regeneron Pharma Novel antigen binding molecule formats.
TW202200618A (en) * 2020-03-17 2022-01-01 美商西雅圖免疫公司 Miniature guidance and navigation control (minignc) antibody-like proteins and methods of making and using thereof
CN111548424A (en) * 2020-06-05 2020-08-18 上海科弈药业科技有限公司 Multifunctional fusion protein targeting EGFR (epidermal growth factor receptor) and CD47 and application thereof
IL301472A (en) * 2020-09-21 2023-05-01 Systimmune Inc Specificity enchanced bispecific antibody (seba)
AU2022333089A1 (en) * 2021-08-25 2024-02-29 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Bispecific tetravalent antibody targeting egfr and her3
WO2023044483A2 (en) * 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
CA3233721A1 (en) * 2021-10-03 2023-04-06 Sa XIAO Methods of treating cancer and the pharmaceutical compositions thereof
CN116120460A (en) * 2021-11-15 2023-05-16 成都百利多特生物药业有限责任公司 Bispecific antibody-camptothecins drug conjugate and medical application thereof
WO2023241480A1 (en) * 2022-06-13 2023-12-21 三优生物医药(上海)有限公司 Anti-pd-l1, vegf and egfr trispecific antibody and use thereof
CN116063564A (en) * 2022-10-08 2023-05-05 盛禾(中国)生物制药有限公司 Method for purifying fusion protein

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2200753B (en) 1986-12-23 1991-01-23 Brookes & Gatehouse Speed measurement device
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
AU2003210802B2 (en) * 2002-02-05 2009-09-10 Genentech Inc. Protein purification
US7332585B2 (en) * 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
UA94213C2 (en) * 2004-09-17 2011-04-26 Домантис Лимитед Use of monovalent antibody polypeptide that inhibits cd40 or cd40l activity in the manufacture of a medicament for treating or preventing autoimmune disease
WO2007147001A2 (en) * 2006-06-14 2007-12-21 Imclone Systems Incorporated Lyophilized formulations of anti-egfr antibodies
CA2670315A1 (en) * 2006-11-21 2008-11-20 The Regents Of The University Of California Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
ES2572728T3 (en) * 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Bispecific anti-HER antibodies
AU2010229705A1 (en) 2009-03-27 2011-10-20 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
CA2756244A1 (en) * 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
MX2011010166A (en) * 2009-04-07 2011-10-11 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies.
KR20120060877A (en) * 2009-09-01 2012-06-12 아보트 러보러터리즈 Dual variable domain immunoglobulins and uses thereof
EP2496598B1 (en) * 2009-11-04 2017-08-02 Affibody AB Her3 binding polypeptides
AU2011307251A1 (en) * 2010-09-30 2013-02-28 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-HER3 antibodies
CN103384681B (en) 2010-12-23 2018-05-18 霍夫曼-拉罗奇有限公司 Bonding agent
TWI622597B (en) 2011-03-28 2018-05-01 賽諾菲公司 Dual variable region antibody-like binding proteins having cross-over binding region orientation
CN103796678B (en) 2011-04-20 2018-02-27 健玛保 For HER2 bispecific antibody
US20140170148A1 (en) * 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2
RS57279B1 (en) * 2011-04-25 2018-08-31 Daiichi Sankyo Co Ltd Anti-b7-h3 antibody
CN102250246A (en) * 2011-06-10 2011-11-23 常州亚当生物技术有限公司 Bispecific antibody to VEGF/PDGFR beta and application thereof
CN102250247B (en) * 2011-06-15 2013-06-19 常州亚当生物技术有限公司 Bispecific antibody to VEGF/ANG2 and application thereof
JP6441079B2 (en) * 2011-12-19 2018-12-19 シンイミューン ゲーエムベーハー Bispecific antibody molecule
CN104144949B (en) 2011-12-22 2016-08-31 财团法人生物技术开发中心 Bispecific T cell activation agent antibody
JP2015514710A (en) * 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Diagnosis and treatment of HER3 inhibitors
WO2014012082A2 (en) * 2012-07-13 2014-01-16 Zymeworks Inc. Multivalent heteromultimer scaffold design an constructs
KR20240005211A (en) * 2012-11-21 2024-01-11 얀센 바이오테크 인코포레이티드 BISPECIFIC EGFR/c-Met ANTIBODIES
CN104650113A (en) * 2012-12-21 2015-05-27 百奥泰生物科技(广州)有限公司 Maytansine derivative as well as preparation method and application thereof
US20160009824A1 (en) 2013-03-15 2016-01-14 Merck Patent Gmbh Tetravalent bispecific antibodies
US9388243B2 (en) * 2013-05-29 2016-07-12 Samsung Electronics Co., Ltd. Method of target membrane protein depletion
CN113150165A (en) 2014-12-22 2021-07-23 西雅图免疫公司 Bispecific tetravalent antibodies and methods of making and using same

Also Published As

Publication number Publication date
EP3237006B1 (en) 2023-08-16
ES2962675T3 (en) 2024-03-20
CN113512122A (en) 2021-10-19
KR20230149328A (en) 2023-10-26
EP3237005A1 (en) 2017-11-01
CN113105551A (en) 2021-07-13
KR20230104988A (en) 2023-07-11
CN113105552A (en) 2021-07-13
EP3237005A4 (en) 2018-05-23
CN113105553A (en) 2021-07-13
KR102548827B1 (en) 2023-06-30
CA2969867A1 (en) 2016-06-30
US20170073418A1 (en) 2017-03-16
IL286835B2 (en) 2024-03-01
CA3138083A1 (en) 2016-06-30
JP2018509175A (en) 2018-04-05
CN113512120A (en) 2021-10-19
JP2021119149A (en) 2021-08-12
WO2016106157A1 (en) 2016-06-30
IL305193A (en) 2023-10-01
CA2969867C (en) 2022-01-25
CN107206074B (en) 2023-12-01
JP6947639B2 (en) 2021-10-13
CN117467017A (en) 2024-01-30
CN113150165A (en) 2021-07-23
CN106659779A (en) 2017-05-10
US20170369587A1 (en) 2017-12-28
SG11201704741PA (en) 2017-07-28
KR102590385B1 (en) 2023-10-18
IL286835B1 (en) 2023-11-01
IL252811A0 (en) 2017-08-31
IL286835A (en) 2021-10-31
CN113512123A (en) 2021-10-19
US10717783B2 (en) 2020-07-21
JP7335290B2 (en) 2023-08-29
EP3237006A4 (en) 2018-05-30
AU2015369831A1 (en) 2017-06-29
KR20170091162A (en) 2017-08-08
US10919977B2 (en) 2021-02-16
EP3237006A1 (en) 2017-11-01
WO2016106158A1 (en) 2016-06-30
CN113512121A (en) 2021-10-19
AU2015369831B2 (en) 2019-07-11
CN106659779B (en) 2021-05-18
CN107206074A (en) 2017-09-26
IL252811B (en) 2021-10-31

Similar Documents

Publication Publication Date Title
NZ732628A (en) Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof
MX2020010382A (en) Bispecific antibodies specific for pd1 and tim3.
PH12019502282A1 (en) Bispecific antibodies specifically binding to pd1 and lag3
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
NZ728749A (en) Anti-pd-l1 antibodies
MX2022011659A (en) Antigen binding proteins that bind pd-l1.
MX2019000730A (en) Multispecific antigen binding proteins and methods of use thereof.
PH12017502019A1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens
MX2021003704A (en) Heterodimeric antibodies that bind cd3 and tumor antigens.
MX2016003593A (en) Multispecific domain exchanged common variable light chain antibodies.
BR112016000666A2 (en) BISPECIFIC CD3 AND CD19 ANTIGEN BINDING CONSTRUCTS
AU2014232501C1 (en) Heterodimeric proteins
MX2015012540A (en) Common light chain mouse.
EA201692504A1 (en) TRISPECIFIC BINDING MOLECULES AND METHODS OF THEIR APPLICATION
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
MX353278B (en) Common light chain mouse.
EA201990672A1 (en) ANTIBODIES SPECIFICALLY RELATING TO PD-1, AND THEIR FUNCTIONAL FRAGMENTS
EA201990673A1 (en) ANTIBODIES SPECIFICALLY BINDING WITH IL-17A, AND THEIR FUNCTIONAL FRAGMENTS
AR105267A1 (en) TAU JOINT ANTIBODIES
EA201992756A3 (en) ANTIBODIES AGAINST CD48 AND THEIR CONJUGATES
MX2016012273A (en) Vl antigen binding proteins exhibiting distinct binding characteristics.
AU2017255888A1 (en) Humanized anti-BASIGIN antibodies and the use thereof
MX2019011585A (en) Stable multispecific antibodies.
DK3265487T3 (en) MODIFIED IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY
MX2020007880A (en) Mica/b antibodies and methods of use.

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: SYSTIMMUNE, INC., US

Effective date: 20190403

Owner name: SICHUAN BAILI PHARMACEUTICAL CO., LTD., CN

Effective date: 20190403

ERR Error or correction

Free format text: THE INVENTOR HAS BEEN CORRECTED TO 3569991, GAO, ZEREN, 2023 120TH AVE. NEBELLEVUE, WASHINGTON 98005, US; 3569992, TAN, PHIL, 2023 120TH AVE. NEBELLEVUE, WASHINGTON 98005, US; 3569993, KOVACEVICH, BRIAN, 2023 120TH AVE. NEBELLEVUE, WASHINGTON 98005, US; 3569994, RENSHAW, BLAIR, 2023 120TH AVE. NEBELLEVUE, WASHINGTON 98005, US; 3569995, ADAMO, JEFFREY, 2023 120TH AVE. NEBELLEVUE, WASHINGTON 98005, US; 3569996, MAK, NGA SZE AMANDA, 2023 120TH AVE. NEBELLEVUE, WASHINGTON 98005, US; 3569997, ZHUO, SHI, ZHONGHAIJINCHENG, NO.8, JINLV ROAD, WUHOU AVENUE, WUHOU DISTRICTCHENGDU, SICHUAN, CN; 3569998, CHEN, LAN, YOUKELIANBANG III, NO.1, DONGJIAWAN NORTH ROAD, WUHOU DISTRICTCHENGDU, SICHUAN, CN; 365477

Effective date: 20190408

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2020 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20190919

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2021 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20201218

ASS Change of ownership

Owner name: BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD., CN

Effective date: 20211029

Owner name: SYSTIMMUNE, INC., US

Effective date: 20211029

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2022 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20211105

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2023 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20220919

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2024 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20230919